Cardiovascular Events in Patients With CAD During Emergent Endoscopy for

Status Recruiting

Clinical Trial Summary

Background:

Upper gastrointestinal (GI) bleeding, a common disorder encountered at emergency room, may cause hypotension and tachycardia that may in turn result in myocardial ischemia in patients with coronary artery disease (CAD). An emergent endoscopy with hemostasis is the mainstay of management. However, endoscopy itself may result in myocardial ischemia. Whether myocardial ischemia and arrhythmia occurs more frequently during emergent endoscopy in patients with CAD remains unknown.

Objective:

To determine whether the risk of myocardial ischemia and arrhythmia is increased during emergent endoscopy in patients with CAD.

Method:

Adult patients with documented CAD undergoing emergent endoscopy due to UGI bleeding are included. Adult patients without CAD undergoing emergent endoscopy due to UGI bleeding were included as the control group. The expected case numbers were 50 patients in each group. Patients with terminal illness, pregnancy, active lung disease requiring ventilator support are excluded. Before endoscopy, symptoms of myocardial ischemia, blood pressure, heart rate, O2 saturation, hemogram, baseline 12-lead EKG, and cardiac enzyme are obtained. All patients are monitored with Holter EKG since 10 minutes before endoscopy to 2 hours after the procedure. Blood pressure, heart rate, and O2 saturation are closely monitored during the procedure. Endoscopy is performed by experienced endoscopist and endoscopic hemostasis is done according to the types of lesions. The duration of endoscopy, types of endoscopic hemostasis, and blood pressure are recorded. After endoscopy, symptoms of myocardial ischemia, blood pressure, heart rate, O2 saturation, hemogram, baseline 12-lead EKG, and cardiac enzyme are checked again.

Keywords: Emergent endoscopy, coronary artery disease, cardiovascular events

Clinical Trial Description

Expected Result and Implication If myocardial ischemia is not increased in CAD patients undergoing emergent endoscopy, then this technique can be used safely in this group of patients. If myocardial ischemia occurs more frequently in CAD patients undergoing emergent endoscopy, we can try to analyze factors associated with increased risk, such as duration of endoscopy, severity of anemia, or drugs used for endoscopic hemostasis. Then we can try to avoid these predisposing factors and increase the safety of emergent endoscopy. ;

Study Design

Observational Model: Defined Population, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00173511
Study type	Observational
Source	National Taiwan University Hospital
Contact	Jyh-ming Liou, MD
Phone	886-2-23123456
Email	dtmed046@ha.mc.ntu.edu.tw
Status	Recruiting
Phase	N/A
Start date	July 2005
Completion date	February 2006

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06032572` - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)	N/A
Completed	`NCT05672862` - International Post-PCI FFR Extended Registry
Completed	`NCT04492423` - VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
Completed	`NCT01205776` - EXCEL Clinical Trial	N/A
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed	`NCT00046410` - Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Not yet recruiting	`NCT02895009` - Hemostatic Compression Patterns After Transradial Coronary Intervention	N/A
Completed	`NCT02784873` - High Intensity Interval Training in UK Cardiac Rehabilitation Programmes	N/A
Completed	`NCT02948517` - Time Restricted Feeding for Weight Loss and Cardio-protection	N/A
Recruiting	`NCT02859480` - Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI	Phase 4
Completed	`NCT02382731` - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction	N/A
Completed	`NCT02510547` - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial	Phase 4
Withdrawn	`NCT02418143` - A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Recruiting	`NCT01681381` - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization	N/A
Completed	`NCT02248415` - Administration of Warm Blood Cardioplegia With or Without Roller Pump	N/A
Recruiting	`NCT01207167` - Mediators of Atherosclerosis in South Asians Living in America
Completed	`NCT02088138` - Functional Electrical Stimulation in Cardiac Patients	N/A
Completed	`NCT02173067` - Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective	N/A
Completed	`NCT02133807` - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cardiovascular Events in Patients With CAD During Emergent Endoscopy for Upper Gastrointestinal Bleeding

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms